BlackRock Advisors’s Acceleron Pharma XLRN Stock Holding History

BlackRock Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$22.7M	Buy	889,177 +236,982	+36%	+$7.51M	0.02%	517
2016 Q3	$23.6M	Buy	652,195 +3,278	+0.5%	+$109K	0.02%	469
2016 Q2	$22.1M	Sell	648,917 -26,292	-4%	-$855K	0.02%	499
2016 Q1	$17.8M	Buy	675,209 +166,393	+33%	+$4.84M	0.02%	576
2015 Q4	$24.8M	Sell	508,816 -673	-0.1%	-$24.2K	0.03%	478
2015 Q3	$12.7M	Buy	509,489 +12,972	+3%	+$390K	0.01%	690
2015 Q2	$15.7M	Buy	496,517 +28,541	+6%	+$921K	0.02%	614
2015 Q1	$17.8M	Buy	467,976 +26,351	+6%	+$1.05M	0.02%	596
2014 Q4	$17.2M	Buy	441,625 +229,088	+108%	+$7.98M	0.02%	601
2014 Q3	$6.43M	Sell	212,537 -24,206	-10%	-$682K	0.01%	909
2014 Q2	$8.04M	Buy	236,743 +7,824	+3%	+$262K	0.01%	847
2014 Q1	$7.9M	Buy	228,919 +19,773	+9%	+$892K	0.01%	865
2013 Q4	$8.28M	Buy	+209,146	New	+$5.05M	0.01%	849

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Advisors's XLRN Position: Q4 2016 in Review

BlackRock Advisors increased its Acceleron Pharma (XLRN) stake by 36% in Q4 2016, buying an estimated $7.51M and bringing the position to 889,177 shares worth $22.7M. The position accounts for 0.02% of the portfolio, ranked #517.

BlackRock Advisors first reported a position in XLRN in Q4 2013 and has held it in 13 quarters since. The position peaked at $24.8M in Q4 2015. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

BlackRock Advisors held 889,177 shares of Acceleron Pharma worth $22.7M as of Q4 2016.
BlackRock Advisors bought 236,982 Acceleron Pharma shares in Q4 2016, an estimated $7.51M.
Acceleron Pharma made up 0.02% of BlackRock Advisors's portfolio in Q4 2016, its #517 holding.
BlackRock Advisors first reported a position in Acceleron Pharma in Q4 2013 and has held it in 13 quarters since.
BlackRock Advisors's Acceleron Pharma position peaked at $24.8M in Q4 2015.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.